Dr Hannah Schiff, Senior Clinical Lecturer and Consultant in Respiratory Medicine at the University of Southampton, is advancing the frontiers of tuberculosis (TB) research through innovative approaches in diagnostics. With a background in natural sciences and medicine, she combines a long-standing interest in infectious diseases with expertise in respiratory medicine. Her current focus on proteomics reflects a drive to develop rapid, accessible TB diagnostics with real-world impact, especially in high-burden, resource-limited settings.

In this Future Leaders interview, Dr Schiff discusses how proteomic technologies are reshaping TB diagnostics, uncovering new biomarkers and biological insights through large-scale data analysis, and the challenges and rewards of balancing clinical work, research, and education.

I have been interested in infectious diseases since my undergraduate degree in Natural Sciences, where I was particularly interested in the body’s immune response to infection in addition to infectious diseases that could cause global pandemics. During my subsequent medical degree, I developed an interest in the anatomy and physiology of the respiratory system, gaining insight into the lung’s role as a vital site for the body’s interaction with infectious pathogens, and how this manifests clinically and radiologically. During my clinical respiratory training in Southampton, I became interested in diagnostics, and I was inspired by working with leading, clinical academics in a centre renowned for respiratory research. This led to the opportunity to study diagnostics in TB.

Proteins are the end effectors of disease and proteomic technologies are enabling the discovery of new protein biomarkers in body fluids like blood, urine and sputum. Diagnostic combinations that could achieve high accuracy, while using a rapid, cheap and easy-to-use test could enable earlier detection of transmissible pulmonary TB, particularly in lower resourced countries which suffer high disease burden.

In addition to discovering new diagnostic markers that are potentially translatable for patient benefit, I am excited to explore how the analysis of large datasets may lead to new biological insights into TB disease, and how TB disease is reflected in the plasma proteome.

This is a challenge! I am finding that it is as much about managing my energy as my time, alongside setting clear and realistic priorities and objectives. I enjoy working as part of a varied team and I really believe that by working together in a team, far more can be achieved than by working alone.

Follow your interests and explore what research projects are taking place at your institution. Talk to clinical academics about their research. Academic medicine takes many forms and by being interested, inquisitive and persistent, research opportunities will arise and unexpected doors may open.

Further content in respiratory infections.

Cite: Hannah Schiff. Harnessing Proteomics to Transform Tuberculosis Diagnostics: a Q&A with Future Leader, Hannah Schiff. touchRESPIRATORY. 15 July 2025.

Editor: Victoria Smith, Senior Content Editor.

Disclosures: This short article was prepared by touchRESPIRATORY in collaboration with Hannah Schiff. touchRESPIRATORY utilize AI as an editorial tool (ChatGPT (GPT-4o) [Large language model]. https://chat.openai.com/chat.) The content was developed and edited by human editors. No fees or funding were associated with its publication.

Hannah Schiff discloses receiving grant/research support from the Medical Research Council (MRC) and the NIHR Academy of Medical Sciences.

touchRESPIRATORY is celebrating the brightest rising stars in respiratory and pulmonary medicine, who are set to shape the future of the field.

View more Future Leaders interviews here.